Protalix BioTherapeutics (PLX) Common Equity (2010 - 2026)

Protalix BioTherapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $67.2 million for Q1 2026.

• In Q1 2026, Common Equity rose 48.71% year-over-year to $67.2 million; the TTM figure through Mar 2026 stood at $67.2 million (up 48.71% YoY), while the FY2025 annual figure was $48.2 million, up 11.62% from the prior year.
• Common Equity was $67.2 million for Q1 2026 at Protalix BioTherapeutics, up from $48.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $67.2 million in Q1 2026 to a low of -$11.5 million in Q3 2022.
• Historically, Common Equity has averaged $27.6 million across 5 years, with a median of $33.6 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Common Equity tumbled 5505.63% in 2022, then surged 2854.96% in 2024.
• A 5-year view of Common Equity shows it stood at -$10.6 million in 2022, then soared by 415.5% to $33.6 million in 2023, then rose by 28.72% to $43.2 million in 2024, then gained by 11.62% to $48.2 million in 2025, then jumped by 39.39% to $67.2 million in 2026.
• The last three Common Equity figures came in at $67.2 million (Q1 2026), $48.2 million (Q4 2025), and $52.9 million (Q3 2025), per Business Quant data.